284 related articles for article (PubMed ID: 12681023)
21. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes.
Raskin P; Rendell M; Riddle MC; Dole JF; Freed MI; Rosenstock J;
Diabetes Care; 2001 Jul; 24(7):1226-32. PubMed ID: 11423507
[TBL] [Abstract][Full Text] [Related]
22. Rosiglitazone monotherapy is effective in patients with type 2 diabetes.
Lebovitz HE; Dole JF; Patwardhan R; Rappaport EB; Freed MI;
J Clin Endocrinol Metab; 2001 Jan; 86(1):280-8. PubMed ID: 11232013
[TBL] [Abstract][Full Text] [Related]
23. Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.
Huang Z; Wan X; Liu J; Deng W; Chen A; Liu L; Liu J; Wei G; Li H; Fang D; Li Y
Diabetes Technol Ther; 2013 Oct; 15(10):859-69. PubMed ID: 23991629
[TBL] [Abstract][Full Text] [Related]
24. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
25. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
26. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
27. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.
Rosenstock J; Goldstein BJ; Vinik AI; O'neill MC; Porter LE; Heise MA; Kravitz B; Dirani RG; Freed MI;
Diabetes Obes Metab; 2006 Jan; 8(1):49-57. PubMed ID: 16367882
[TBL] [Abstract][Full Text] [Related]
28. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
[TBL] [Abstract][Full Text] [Related]
29. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes.
Chou HS; Palmer JP; Jones AR; Waterhouse B; Ferreira-Cornwell C; Krebs J; Goldstein BJ
Diabetes Obes Metab; 2008 Aug; 10(8):626-37. PubMed ID: 17645558
[TBL] [Abstract][Full Text] [Related]
30. A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and tolerability of combination therapy with rosiglitazone and sulfonylurea in African American and Hispanic American patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy.
Davidson JA; McMorn SO; Waterhouse BR; Cobitz AR
Clin Ther; 2007 Sep; 29(9):1900-14. PubMed ID: 18035190
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
Beale S; Bagust A; Shearer AT; Martin A; Hulme L
Pharmacoeconomics; 2006; 24 Suppl 1():21-34. PubMed ID: 16800160
[TBL] [Abstract][Full Text] [Related]
32. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes.
Hällsten K; Virtanen KA; Lönnqvist F; Sipilä H; Oksanen A; Viljanen T; Rönnemaa T; Viikari J; Knuuti J; Nuutila P
Diabetes; 2002 Dec; 51(12):3479-85. PubMed ID: 12453903
[TBL] [Abstract][Full Text] [Related]
33. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.
de Winter W; DeJongh J; Post T; Ploeger B; Urquhart R; Moules I; Eckland D; Danhof M
J Pharmacokinet Pharmacodyn; 2006 Jun; 33(3):313-43. PubMed ID: 16552630
[TBL] [Abstract][Full Text] [Related]
34. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Derosa G; Mereu R; Salvadeo SA; D'Angelo A; Ciccarelli L; Piccinni MN; Ferrari I; Gravina A; Maffioli P; Cicero AF
Intern Med; 2009; 48(5):265-71. PubMed ID: 19252346
[TBL] [Abstract][Full Text] [Related]
35. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.
Finegood DT; McArthur MD; Kojwang D; Thomas MJ; Topp BG; Leonard T; Buckingham RE
Diabetes; 2001 May; 50(5):1021-9. PubMed ID: 11334404
[TBL] [Abstract][Full Text] [Related]
36. Effects of metformin and rosiglitazone on peripheral insulin resistance and β-cell function in obesity: a double-blind, randomized, controlled study.
Li X; Zhang N; Li Y; Shi Y; Li D; Xie Y; Xie Y; Ming J
J Int Med Res; 2011; 39(2):358-65. PubMed ID: 21672339
[TBL] [Abstract][Full Text] [Related]
37. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
[TBL] [Abstract][Full Text] [Related]
38. Addition of rosiglitazone to glimepirid and metformin combination therapy in type 2 diabetes.
Orbay E; Sargin M; Sargin H; Gözü H; Bayramiçli OU; Yayla A
Endocr J; 2004 Dec; 51(6):521-7. PubMed ID: 15644569
[TBL] [Abstract][Full Text] [Related]
39. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients.
Barnett AH; Grant PJ; Hitman GA; Mather H; Pawa M; Robertson L; Trelfa A;
Diabet Med; 2003 May; 20(5):387-93. PubMed ID: 12752488
[TBL] [Abstract][Full Text] [Related]
40. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes.
Buch HN; Baskar V; Barton DM; Kamalakannan D; Akarca C; Singh BM
Diabet Med; 2002 Jul; 19(7):572-4. PubMed ID: 12099960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
